Finance Watch: VC Enthusiasm For Biopharma Continues As 5AM Ventures Raises $750m

Antimicrobial Firms Get A Boost From Two Sources

Private Company Edition: 5AM revealed two funds totaling $450m and $300m, V-Bio raised a €110m venture capital fund and AXA IM Alts committed $500m for health care private equity deals. Also, TRIANA launched with $110m and the AMR Action Fund backs Adaptive Phage Therapeutics.

Finance Watch Private Company
• Source: Shutterstock

Venture capital investment in private biopharmaceutical companies seems to have kept up a strong pace in 2022 relative to investment in publicly traded drug developers, which have been challenged to raise money this year while their stock prices largely have been in decline. Several private companies have raised significant VC funding rounds and many venture firms have raised large new funds – including, most recently, 5AM Ventures with $750m across two funds.

While initial public offerings have been limited in 2022 compared with the last two years, which both produced record-breaking IPO...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.